Skip to content
For research use only. Not for human or veterinary use. Not a drug, food, or dietary supplement.
AMIRAVOResearch Library
Cycle-length evidence

CJC-1295 (with DAC) cycle length: what human studies ran

Not approved — research use onlyBLimited human data
Short answer: there is no established CJC-1295 (with DAC) cycle length, and we found no human studies that report one.

Treatment and follow-up in human studies

No human study durations are recorded.

What has not been tested

  • On-and-off schedules or breaks between courses.
  • Repeated courses and long-term exposure beyond the periods listed.
  • CJC-1295 (with DAC) combined with other compounds, unless a study above says so.

Frequently asked questions

Is there an established CJC-1295 (with DAC) cycle length?
No. We found no human studies that report a treatment duration for CJC-1295 (with DAC).
What is the longest human study of CJC-1295 (with DAC)?
None is recorded.
Do study durations tell me how long to use something?
No. A study duration is how long investigators administered a compound to selected participants under monitoring. It is not a recommended course, and a break between courses has not been tested for any compound on this site that is not approved.
CJC-1295 (with DAC) dosing reference Full research page

References

  1. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults J Clin Endocrinol Metab. 2006
  2. Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse Am J Physiol Endocrinol Metab. 2006
  3. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog Endocrinology. 2005
  4. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog J Clin Endocrinol Metab. 2006
  5. A Study to Evaluate CJC 1295 in HIV Patients With Visceral Obesity (NCT00267527) ClinicalTrials.gov. 2006
  6. Pharmacy Compounding Advisory Committee Meeting, December 4, 2024: FDA presentations on CJC-1295-related bulk drug substances FDA. 2024
  7. Substances in Compounding that May Present Significant Safety Risks FDA. 2024
  8. WADA Prohibited List US Food and Drug Administration. 2026
  9. CJC-1295 (CID 91971820) PubChem. 2026
  10. DailyMed drug label search for CJC-1295 (zero labels returned on 22 Oct 2026) DailyMed (NLM). 2026
  11. Pharmacy Compounding Advisory Committee, December 4, 2024: FDA briefing document and points to consider for CJC-1295-related bulk drug substances FDA. 2024